Structural States of Hdm2 and HdmX: X‐ray Elucidation of Adaptations and Binding Interactions for Different Chemical Compound Classes

Hdm2 (human MDM2, human double minute 2 homologue) counteracts p53 function by direct binding to p53 and by ubiquitin‐dependent p53 protein degradation. Activation of p53 by inhibitors of the p53–Hdm2 interaction is being pursued as a therapeutic strategy in p53 wild‐type cancers. In addition, HdmX (human MDMX, human MDM4) was also identified as an important therapeutic target to efficiently reactivate p53, and it is likely that dual inhibition of Hdm2 and HdmX is beneficial. Herein we report four new X‐ray structures for Hdm2 and five new X‐ray structures for HdmX complexes, involving different classes of synthetic compounds (including the worldwide highest resolutions for Hdm2 and HdmX, at 1.13 and 1.20 Å, respectively). We also reveal the key additive 18‐crown‐ether, which we discovered to enable HdmX crystallization and show its stabilization of various Lys residues. In addition, we report the previously unpublished details of X‐ray structure determinations for eight further Hdm2 complexes, including the clinical trial compounds NVP‐CGM097 and NVP‐HDM201. An analysis of all compound binding modes reveals new and deepened insight into the possible adaptations and structural states of Hdm2 (e.g., flip of F55, flip of Y67, reorientation of H96) and HdmX (e.g., flip of H55, dimer induction), enabling key binding interactions for different compound classes. To facilitate comparisons, we used the same numbering for Hdm2 (as in Q00987) and HdmX (as in O15151, but minus 1). Taken together, these structural insights should prove useful for the design and optimization of further selective and/or dual Hdm2/HdmX inhibitors.

[1]  Joerg Kallen,et al.  Discovery of a Dihydroisoquinolinone Derivative (NVP-CGM097): A Highly Potent and Selective MDM2 Inhibitor Undergoing Phase 1 Clinical Trials in p53wt Tumors. , 2015, Journal of medicinal chemistry.

[2]  A. Verma,et al.  Dual inhibition of MDMX and MDM2 as a therapeutic strategy in leukemia , 2018, Science Translational Medicine.

[3]  P. Furet,et al.  Tetra-substituted imidazoles as a new class of inhibitors of the p53-MDM2 interaction. , 2014, Bioorganic & medicinal chemistry letters.

[4]  D. Lane,et al.  Drugging the p53 pathway: understanding the route to clinical efficacy , 2014, Nature Reviews Drug Discovery.

[5]  P. Furet,et al.  Discovery of potent antagonists of the interaction between human double minute 2 and tumor suppressor p53. , 2000, Journal of medicinal chemistry.

[6]  A. Levine.  Targeting Therapies for the p53 Protein in Cancer Treatments , 2019, Annual Review of Cancer Biology.

[7]  A. Levine,et al.  The p53 pathway: positive and negative feedback loops , 2005, Oncogene.

[8]  Wei Gu,et al.  Modes of p53 Regulation , 2009, Cell.

[9]  Alexander Dömling,et al.  Transient protein states in designing inhibitors of the MDM2-p53 interaction. , 2013, Structure.

[10]  Philipp Holzer,et al.  In vitro and in vivo characterization of a novel, highly potent p53-MDM2 inhibitor. , 2018, Bioorganic & medicinal chemistry letters.

[11]  Constantinos G. Neochoritis,et al.  Rational design and synthesis of 1,5-disubstituted tetrazoles as potent inhibitors of the MDM2-p53 interaction. , 2017, European journal of medicinal chemistry.

[12]  Thelma Thompson,et al.  Activation of the p53 pathway by small-molecule-induced MDM2 and MDMX dimerization , 2012, Proceedings of the National Academy of Sciences.

[13]  P. Furet,et al.  The central valine concept provides an entry in a new class of non peptide inhibitors of the p53-MDM2 interaction. , 2012, Bioorganic & Medicinal Chemistry Letters.

[14]  Philipp Holzer,et al.  Discovery of a novel class of highly potent inhibitors of the p53-MDM2 interaction by structure-based design starting from a conformational argument. , 2016, Bioorganic & medicinal chemistry letters.

[15]  M. Oren,et al.  The p53-Mdm2 module and the ubiquitin system. , 2003, Seminars in cancer biology.

[16]  H. Kawai,et al.  The p53 inhibitors MDM2/MDMX complex is required for control of p53 activity in vivo , 2011, Proceedings of the National Academy of Sciences.

[17]  Constantinos G. Neochoritis,et al.  How To Design a Successful p53–MDM2/X Interaction Inhibitor: A Thorough Overview Based on Crystal Structures , 2016, ChemMedChem.

[18]  Gopal L. Khatik,et al.  p53-Mdm2 Interaction Inhibitors as Novel Nongenotoxic Anticancer Agents. , 2017, Current cancer drug targets.

[19]  Eric Y. Durand,et al.  Dose and Schedule Determine Distinct Molecular Mechanisms Underlying the Efficacy of the p53-MDM2 Inhibitor HDM201. , 2018, Cancer research.

[20]  Chao-Yie Yang,et al.  Targeting the MDM2-p53 Protein-Protein Interaction for New Cancer Therapy: Progress and Challenges. , 2017, Cold Spring Harbor perspectives in medicine.

[21]  A. Levine,et al.  Structure of the MDM2 Oncoprotein Bound to the p53 Tumor Suppressor Transactivation Domain , 1996, Science.

[22]  Nathan Brown,et al.  Knowledge-based virtual screening: application to the MDM4/p53 protein-protein interaction. , 2009, Methods in molecular biology.

[23]  I. Irminger-Finger,et al.  Mutational spectrum of p53 mutations in primary breast and ovarian tumors. , 2004, Critical reviews in oncology/hematology.

[24]  Jinn-Moon Yang,et al.  Crowning Proteins: Modulating the Protein Surface Properties using Crown Ethers** , 2014, Angewandte Chemie.

[25]  M. Geiser,et al.  Crystal Structures of Human MdmX (HdmX) in Complex with p53 Peptide Analogues Reveal Surprising Conformational Changes* , 2009, Journal of Biological Chemistry.

[26]  L. Donehower,et al.  Reduction of p53 gene dosage does not increase initiation or promotion but enhances malignant progression of chemically induced skin tumors , 1993, Cell.

[27]  E. Jacoby,et al.  Discovery of dihydroisoquinolinone derivatives as novel inhibitors of the p53-MDM2 interaction with a distinct binding mode. , 2015, Bioorganic & medicinal chemistry letters.

[28]  Maria M. M. Santos,et al.  An Update on MDMX and Dual MDM2/X Inhibitors. , 2018, Current topics in medicinal chemistry.

[29]  T. Holak,et al.  Structure of the human Mdmx protein bound to the p53 tumor suppressor transactivation domain , 2008, Cell cycle.

[30]  R. Benezra,et al.  Chapter Fifteen – Targeting Protein–Protein Interactions to Treat Cancer—Recent Progress and Future Directions , 2013 .

[31]  Y. Wang,et al.  Discovery of AMG 232, a potent, selective, and orally bioavailable MDM2-p53 inhibitor in clinical development. , 2014, Journal of medicinal chemistry.

[32]  Eberhardt Herdtweck,et al.  2,30-Bis(10H-indole) heterocycles: New p53/MDM2/MDMX antagonists. , 2015, Bioorganic & medicinal chemistry letters.

[33]  D. Lane,et al.  p53, guardian of the genome , 1992, Nature.

[34]  P. Secchiero,et al.  MDM2/X inhibitors under clinical evaluation: perspectives for the management of hematological malignancies and pediatric cancer , 2017, Journal of Hematology & Oncology.

[35]  G. Wahl,et al.  MDM2, MDMX and p53 in oncogenesis and cancer therapy , 2013, Nature Reviews Cancer.